Why MacroGenics, Inc. Stock Soared Today
Shares of the clinical-stage oncology and autoimmune disease specialist MacroGenics (NASDAQ: MGNX) ended the day higher by a healthy 17.36% on a whopping 17.5 times the average volume.
The catalyst? Macrogenics' shares took flight after the company announced a licensing deal with Incyte Corp. (NASDAQ: INCY) for its programmed cell-death protein 1 (PD-1) inhibitor, MGA012, that's being assessed in four solid tumor types in an early-stage dose-escalation study.
Image source: Getty Images.
Source: Fool.com
Incyte Corp. Aktie
55,26 €
-1,16 %
Die Incyte Corp. Aktie sieht ein leichtes Übergewicht bei Buy-Einschätzungen.
Das Kursziel von 77 € für Incyte Corp. impliziert eine deutliche Steigerung um über 20% gegenüber 55.26 €.
